After single-blind placebo run-in periods of ≤7 days, patients were randomly assigned to 3 weeks of sublingual asenapine (10 mg twice daily [BID] on day 1, flexible-dose 5 or 10 mg BID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback